Shareholder Alert: Ademi LLP investigates whether Satsuma Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Shin Nippon

MILWAUKEE, May 1, 2023 /PRNewswire/ -- Ademi LLP is investigating Satsuma (NASDAQ: STSA) for possible breaches of fiduciary duty and other violations of law in its transaction with Shin Nippon. 

Click here to learn how to join the action https://www.ademilaw.com/case/satsuma-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you.

Satsuma's shareholders are expected to receive only $0.91 per share in cash plus one non-tradeable CVR worth up to $5.77 per share in cash. CVR holders will be entitled to receive payments related to proceeds received by Shin Nippon in a future transaction involving STS101, including a potential sale, license, or other grant of rights. The CVR is based on cumulative proceeds received by Shin Nippon after making certain deductions. The transaction agreement unreasonably limits competing bids for Satsuma by imposing a significant penalty if Satsuma accepts a superior bid. Satsuma insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Satsuma's board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Satsuma.

If you own Satsuma common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/satsuma-pharmaceuticals-inc.                       

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP                                                                                       
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

SOURCE Ademi LLP